Online inquiry

IVTScrip™ mRNA-Anti-IFNA1, MDX-1103(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ11137MR)

This product GTTS-WQ11137MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets IFNA1 gene. The antibody can be applied in Dermatomyositis research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_024013.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3439
UniProt ID P01562
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IFNA1, MDX-1103(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ11137MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10262MR IVTScrip™ mRNA-Anti-C5, LFG 316(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA LFG 316
GTTS-WQ6546MR IVTScrip™ mRNA-Anti-TNF, D2E7(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA D2E7
GTTS-WQ7888MR IVTScrip™ mRNA-Anti-MAG, GSK-249320(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA GSK-249320
GTTS-WQ5248MR IVTScrip™ mRNA-Anti-S, CB-6(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CB-6
GTTS-WQ14993MR IVTScrip™ mRNA-Anti-CD19, SJ25C1 scFv-28Z CAR(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA SJ25C1 scFv-28Z CAR
GTTS-WQ3479MR IVTScrip™ mRNA-Anti-pcrV, BA1126(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA BA1126
GTTS-WQ10339MR IVTScrip™ mRNA-Anti-IL17A&TNFSF13B, LY 3090106(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA LY 3090106
GTTS-WQ3835MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, BCD-054(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BCD-054
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW